Search research articles
Contact Us
Filters
Showing results (241-250 of 275) with videos related to
Page
of 28
Sort By:
Critical Reviews in Oncology/Hematology
|
October 23, 2023
Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trials
Daniele Marinelli, Filippo Tommaso Gallina, Sergio Pannunzio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 17, 2019
Crizotinib in <i>MET</i>-Deregulated or <i>ROS1</i>-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial
Lorenza Landi, Rita Chiari, Marcello Tiseo, et al.
Lancet (London, England)
|
June 17, 2014
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
Edward B Garon, Tudor-Eliade Ciuleanu, Oscar Arrieta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 11, 2015
Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort
Julien Mazières, Gérard Zalcman, Lucio Crinò, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 24, 2025
Brief Report: Post Hoc Validation of Platinum Ineligibility in NSCLC From the Phase III IPSOS Study
Solange Peters, Christian Schulz, Martin Reck, et al.
JAMA Oncology
|
May 22, 2025
Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell Lung Cancer
Biagio Ricciuti, Francesca Fusco, Alissa Cooper, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 31, 2022
Detection of ALK fusion variants by RNA-based NGS and clinical outcome correlation in NSCLC patients treated with ALK-TKI sequences
Fabrizio Tabbò, Lucia Anna Muscarella, Elisa Gobbini, et al.
Cancers
|
October 14, 2022
The Impact of the Hippo Pathway and Cell Metabolism on Pathological Complete Response in Locally Advanced Her2+ Breast Cancer: The TRISKELE Multicenter Prospective Study
Eriseld Krasniqi, Francesca Sofia Di Lisa, Anna Di Benedetto, et al.
Gut
|
July 12, 2014
FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study
Ravit Geva, Loredana Vecchione, Konstantinos T Kalogeras, et al.
Ebiomedicine
|
February 10, 2024
Tumoral and stromal hMENA isoforms impact tertiary lymphoid structure localization in lung cancer and predict immune checkpoint blockade response in patients with cancer
Francesca Di Modugno, Anna Di Carlo, Sheila Spada, et al.
Page
of 28
Search research articles
Search
Showing results (241-250 of 275) with videos related to
Sort By:
Page
of 28
Critical Reviews in Oncology/Hematology
|
October 23, 2023
Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trials
Daniele Marinelli, Filippo Tommaso Gallina, Sergio Pannunzio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 17, 2019
Crizotinib in <i>MET</i>-Deregulated or <i>ROS1</i>-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial
Lorenza Landi, Rita Chiari, Marcello Tiseo, et al.
Lancet (London, England)
|
June 17, 2014
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
Edward B Garon, Tudor-Eliade Ciuleanu, Oscar Arrieta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 11, 2015
Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort
Julien Mazières, Gérard Zalcman, Lucio Crinò, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 24, 2025
Brief Report: Post Hoc Validation of Platinum Ineligibility in NSCLC From the Phase III IPSOS Study
Solange Peters, Christian Schulz, Martin Reck, et al.
JAMA Oncology
|
May 22, 2025
Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell Lung Cancer
Biagio Ricciuti, Francesca Fusco, Alissa Cooper, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 31, 2022
Detection of ALK fusion variants by RNA-based NGS and clinical outcome correlation in NSCLC patients treated with ALK-TKI sequences
Fabrizio Tabbò, Lucia Anna Muscarella, Elisa Gobbini, et al.
Cancers
|
October 14, 2022
The Impact of the Hippo Pathway and Cell Metabolism on Pathological Complete Response in Locally Advanced Her2+ Breast Cancer: The TRISKELE Multicenter Prospective Study
Eriseld Krasniqi, Francesca Sofia Di Lisa, Anna Di Benedetto, et al.
Gut
|
July 12, 2014
FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study
Ravit Geva, Loredana Vecchione, Konstantinos T Kalogeras, et al.
Ebiomedicine
|
February 10, 2024
Tumoral and stromal hMENA isoforms impact tertiary lymphoid structure localization in lung cancer and predict immune checkpoint blockade response in patients with cancer
Francesca Di Modugno, Anna Di Carlo, Sheila Spada, et al.
Page
of 28